BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
BLADECO YATIRIM
Bladeco drives sustainable transformation with innovative energy technologies. From fast chargers and solar panels to AI and software solutions, we design systems that boost efficiency and shape the green energy future connecting Türkiye’s innovation with global impact.
Birla Carbon_Nanocyl
Nanocyl SA is the industrial multiwall carbon nanotubes (MWCNT) expert and a worldwide industry leader in the development, manufacturing and sales of MWCNT and MWCNT formulated products. With its 460tons/year annual MWCNT production capacity, Nanocyl has been serving the automotive, electronic and battery industries for almost 20 years with its MWCNTs. In lithium-ion batteries, MWCNT are used as conductive additives in cathode and anode formulations. Thanks to their unique morphology and intrinsinc properties, MWCNT improve internal conductivity, capacity and capacity retention performances. To ease the incorporation of our MWCNTs in electrode slurries, pre-dispersions are available in both water (Aquacyl product range) and NMP (Orgacyl product range). Please visit our booth for more information.
BioVersys AG
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (alpibectir, Phase 2a, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. | BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ready), and tuberculosis (alpibectir, Phase 2a, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.
biotechrabbit GmbH
biotechrabbit is determined to offer the best products and services to those who lead the way in research. The valued relationships with our partners and customers drive us to exceed current limitations with flexibility, innovation and highly customized solutions to match their specific requirements. Each member of our team of highly engaged scientists, experienced managers and talented business developers aims to facilitate our partners and customers to leap and lead progress in the life science. Covering the whole workflow from enzyme production, ReadyMix development and lyophilization, biotechrabbit is the partner of choice for supplying molecular biology enzymes, reagents and mixes to diagnostics and life sciences. Our way of doing business combines the passion and pure curiosity of excellent researchers with the agile spirit of true entrepreneurs. | Covering the whole workflow from enzyme production, ReadyMix development and lyophilization, biotechrabbit is the partner of choice for supplying molecular biology enzymes, reagents and mixes to diagnostics and life sciences. biotechrabbit is determined to offer the best products and services to those who lead the way in research. The valued relationships with our partners and customers drive us to exceed current limitations with flexibility, innovation and highly customized solutions to match their specific requirements. Each member of our team of highly engaged scientists, experienced managers and talented business developers aims to facilitate our partners and customers to leap and lead progress in the life science. Our way of doing business combines the passion and pure curiosity of excellent researchers with the agile spirit of true entrepreneurs.
BIOTECHNOLOGY VALLEY
The Biotechnology Industrialists’ Association (BİYOSAD) aims to drive human development via innovative, high value-added products and services and is establishing the Biotechnology Valley within the Biotechnology Specialized Industrial Zone (BİOSB) in Istanbul. This project aspires to situate Turkey among the world’s leading biotechnology hubs. Biotechnology Valley, positioned in strategically located Tuzla, Istanbul, is a comprehensive initiative designed to create a specialized biotechnology ecosystem. The project aims to boost Turkey’s global presence in the biotechnology market through strong collaborations between business, academia, and the government. It spans 2.7 million square meters and will feature technology development zones, R&D centers, testing and calibration labs, patent offices, and specialized biotechnology schools. Our goal is to enhance global export potential by fostering domestic production of high value-added biotechnology products. We prioritize guiding industry and academia toward innovative collaboration, exploring nature’s possibilities in light of science. Our mission extends beyond meeting current demands to making a positive impact for future generations through sustainable and collaborative efforts. Biotechnology Valley is dedicated to enabling breakthrough technologies in the sector and hosting research that benefits society, adding value to both science and business. We are committed to providing a safe, innovative, and supportive business environment for all sector stakeholders. Join us as a partner in transforming Türkiye and the world into a leading biotechnology center. | Biotechnology Valley is a strategic technology and innovation ecosystem established under the leadership of the Biotechnology Industrialists Association (BIYOSAD) to lead Türkiye’s vision in biotechnology across science, technology, and production. Bringing together the public sector, industry, academia, and investors, the Valley aims to build a high–value-added, sustainable, and globally competitive biotechnology infrastructure. Located in Tepeören, Istanbul, and spanning approximately 2.7 million square meters, Biotechnology Valley is one of Türkiye’s most comprehensive biotechnology initiatives. With its advanced R&D centers, technology development zones, modern manufacturing facilities, and shared infrastructure, the Valley is designed as an integrated hub for local and international companies operating in pharmaceuticals, biotechnology products, medical technologies, and advanced life sciences. Biotechnology Valley is not only a center for production and R&D, but also a living and innovation ecosystem with sustainability at its core. The project prioritizes energy-efficient infrastructure, renewable energy solutions, water efficiency practices, integrated waste management systems, and comprehensive strategies to reduce carbon footprint. This approach positions biotechnology production in harmony with nature and with a strong sense of responsibility toward future generations. The Valley offers a collaborative, innovative, and scalable ecosystem for a wide range of stakeholders, from start-ups and research institutions to global players and investment funds. Through its open innovation approach, Biotechnology Valley promotes knowledge sharing and co-creation, aiming to integrate Türkiye’s biotechnology potential into the global value chain. With its robust infrastructure, sustainability-driven framework, and international vision, Biotechnology Valley continues to advance with determination toward becoming a regional and global center for biotechnology.
BioSpherix, LLC
BioSpherix stands at the forefront of advanced cell and tissue culture technology, dedicated to providing Cytocentric® environments designed for optimal cell care. Our flagship product, the Xvivo System, exemplifies this commitment. By harnessing our proprietary closed-system technology, the Xvivo System revolutionizes cell science and is expertly tailored to meet the demands of your GMP or R&D protocols. This modular and cost-effective system features patented self-sterilizing technology, offering a superior alternative to traditional open systems that expose cell and tissue cultures to unpredictable and non-physiologic conditions. The Xvivo System enhances operational efficiency, adapts to your evolving needs, minimizes contamination risks, and ultimately cultivates healthier, more robust cells. At BioSpherix, our philosophy is Cytocentric®: prioritizing the needs of cells above all else.
BIOSYNTH
Securing Life Sciences Supply Chains – where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, we are science led and customer-focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capabilities run across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Supplying the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. | Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals – where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, we are science led and customer-focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capabilities run across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Supplying the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Find out more at www.biosynth.com. | Securing Life Sciences Supply Chains – where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio and end-to-end manufacturing services, we are science led and customer focused to solve problems and deliver key reagents at scale and quality. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is an innovative life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than half a million products in our research catalog and hundreds of complex manufacturing service projects. Our complex chemistry specialties include enzyme substrates, carbohydrate and nucleoside chemistry, with manufacturing services from the first idea to the finished product, from route scouting to GMP or ton scale production. For peptides, we also have a full end-to-end offering, from lead discovery and optimization, library production, through to GMP NCE or Neoantigen projects. Across biologics we have a synergistic offering, with an extensive range of custom bioprocessing enzyme projects for production of key products. We are also able to offer custom antibody projects, and epitope mapping. Through the Biosynth group we also offer development of antibodies, antigens and supply of plasma for in vitro diagnostics. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. Our main chemical research and manufacturing laboratories are in Switzerland, the United Kingdom, Slovakia and China, with peptide production in the USA and the Netherlands. Enzyme projects are based in Austria and biological IVD reagents in Ireland. Our R&D resources and production facilities are modern and versatile, allowing us to produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale.